Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-resistant Recurrent Ovarian Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)UnknownNCT03542669
What this trial is testing

Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer

Who this might be right for
Recurrent Ovarian CarcinomaPlatinum-resistant Ovarian Cancer
Peking University People's Hospital 9
Testing effectiveness (Phase 2)Looking for participantsNCT05753826
What this trial is testing

Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.

Who this might be right for
Ovarian NeoplasmsOvarian Diseases
Fujian Cancer Hospital 37
Testing effectiveness (Phase 2)Ended earlyNCT06865677
What this trial is testing

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Who this might be right for
Recurrent Platinum Resistant Epithelial Ovarian CarcinomaRecurrent Epithelial Endometrial CarcinomaRecurrent Epithelial Cervical Carcinoma
National Cancer Institute (NCI) 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT02101775
What this trial is testing

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Ovarian Brenner TumorOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid Adenocarcinoma+9 more
National Cancer Institute (NCI) 124
Testing effectiveness (Phase 2)Study completedNCT02953457
What this trial is testing

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene MutationOvarian Serous Adenocarcinoma+3 more
Roswell Park Cancer Institute 40
Testing effectiveness (Phase 2)WithdrawnNCT02948101
What this trial is testing

PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT00023907
What this trial is testing

Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Ended earlyNCT02107378
What this trial is testing

Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma

Who this might be right for
Epithelial Ovarian Carcinoma
SOTIO a.s. 22
Early research (Phase 1)Study completedNCT03508570
What this trial is testing

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Who this might be right for
Malignant Peritoneal NeoplasmMalignant Retroperitoneal NeoplasmMetastatic Cervical Carcinoma+31 more
M.D. Anderson Cancer Center 26
Testing effectiveness (Phase 2)Study completedNCT01447706
What this trial is testing

MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Merrimack Pharmaceuticals 223
Not applicableEnded earlyNCT05891197
What this trial is testing

A Biomarker Screening Protocol for Participants With Solid Tumors

Who this might be right for
Triple Negative Breast CancerNon-small Cell Lung CancerNon Small Cell Lung Cancer+19 more
Lyell Immunopharma, Inc. 10
Early research (Phase 1)Active Not RecruitingNCT04092270
What this trial is testing

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Who this might be right for
Endometrial High Grade Endometrioid AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+26 more
National Cancer Institute (NCI) 55
Testing effectiveness (Phase 2)Ended earlyNCT03587129
What this trial is testing

Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
First Affiliated Hospital of Harbin Medical University 1
Testing effectiveness (Phase 2)Looking for participantsNCT05983276
What this trial is testing

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Who this might be right for
Ovarian Cancer
Loyola University 40
Testing effectiveness (Phase 2)Study completedNCT01481701
What this trial is testing

A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma

Who this might be right for
Ovarian CarcinomaRelapse
Jules Bordet Institute 90
Testing effectiveness (Phase 2)Study completedNCT00006028
What this trial is testing

Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Early research (Phase 1)Looking for participantsNCT04633239
What this trial is testing

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Who this might be right for
Recurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Platinum-Resistant Ovarian Carcinoma
National Cancer Institute (NCI) 42
Testing effectiveness (Phase 2)Looking for participantsNCT05231122
What this trial is testing

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Who this might be right for
Ovarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous Adenocarcinoma+12 more
Roswell Park Cancer Institute 80
Early research (Phase 1)Ended earlyNCT03924245
What this trial is testing

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Who this might be right for
Fallopian Tube CancerFallopian Tube CarcinosarcomaFallopian Tube Clear Cell Adenocarcinoma+10 more
Vanderbilt-Ingram Cancer Center 3
Not applicableUnknownNCT01372787
What this trial is testing

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Who this might be right for
AnxietyFatigueNausea and Vomiting+20 more
Gynecologic Oncology Group 103
Next Page